longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Zhejiang ALK received the "Drug Registration Certificate" for Amlodipine Besylate Tablets from the U.S

Zhitong
Oct 13, 2025 at 08:40 AM

Recently, Zhejiang ALK Pharmaceuticals Co., Ltd. received the "Drug Registration Certificate" for Measartan Potassium Tablets issued by the National Medical Products Administration. The generic name of this drug is Measartan Potassium Tablets, with main ingredient Measartan Potassium, available in two specifications: 40mg and 80mg. The approval number is valid until September 29, 2030. Measartan Potassium Tablets can be used to treat primary hypertension in adults, and the company received the acceptance notice in 2024. This approval is considered equivalent to passing the consistency evaluation, which will enrich the company's product pipeline. However, due to the particularity of the pharmaceutical industry, drug sales are affected by policies, market conditions, and other factors, making the specific sales situation uncertain. The company reminds investors to pay attention to risks

Source: Zhitong The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.

ALK

ALK

002940.SZ

Open

--

High

--

Low

--

Prev Close

--

P/ETTM

--

Market Cap

--

LongbridgeAI